This is a prospective, multicenter, single-arm, phase 2 trial. The aim of this study is to evaluate the efficacy and safety of herombopag combined with cyclosporine for patients with non severe aplastic anemia (NSAA).

This study aims to improve the 24 weeks response rate. The sample size is calculated based on Simon's two-stage design. The first stage of the study enrolled a cohort of 15 patients. If after 24 weeks at least 9 patients achieved a response, then enrollment was expanded to a total of 43 patients. The null hypothesis was unaccepted if more than 26 of 43 patients achieved the response. Accounting for a 20% dropout rate, the estimated final sample size was 54 patients.

Inclusion Criteria:

• Willing and able to comply with the requirements for this study and written informed consent.
• Male or female age ≥ 18 years
• Diagnosis of untreated non severe aplastic anemia.
• Platelet counts < 50 x 10^9/L at least 2 times consecutively (time interval ≥ 1 week)

Exclusion Criteria:

• Receive immunosuppressive therapy more than 4 weeks before enrollment
• Treatment with TPO-RA within 1 week before enrollment
• Inherited bone marrow failure syndromes
• Bone marrow fibrosis grade ≥ 2
• The presence of hemolytic PNH clone
• The presence of clonal karyotypic abnormalities (del(20q), +8 and -Y are not included in this category)
• Previously treated with TPO-RA ≥ 4 weeks
• Previously received immunosuppressive therapy ≥ 12 weeks
• Ferritin > 1000 ng/ml (The increased level of Ferritin led by infection is not included in this category)
• Have an allergy to eltrombopag or any other part of this medicine.
• History of radiotherapy and chemotherapy for malignant solid tumors
• Cytopenia caused by other non-hematologic diseases, including liver cirrhosis, active rheumatic connective tissue disease, and persistence of infectious diseases, etc
• Abnormal liver function: ALT or AST > 3 ULN, or TBil > 1.5 ULN after treatment.
• Abnormal kidney function: Creatinine clearance < 30 ml/min, or serum creatinine (sCr) >1.5 ULN
• Patients with diabetic nephropathy, neuropathy, or eye disease
• Patients with poorly controlled hypertension or cardiac arrhythmia
• Patients with congestive heart failure and the NYHA grade ≥ 3 historically or currently, and LVEF < 45% within 4 weeks before enrollment
• History of arteriovenous thrombosis within 1 year before enrollment
• Participation in another clinical trial within 4 months before the start of this trial
• Pregnant or breast-feeding patients
• Patients considered to be ineligible for the study by the investigator for reasons other than the above